摘要
抗IgE单克隆抗体目前已被批准用于治疗哮喘和慢性荨麻疹,同时抗IgE单克隆抗体联合变应原特异性免疫治疗(AIT)作为过敏性疾病的辅助治疗已引起普遍关注。研究表明,在AIT治疗中或治疗前添加抗IgE单克隆抗体可显著减少AIT不良反应的发生频率和严重程度,明显改善症状评分,缩短达到维持剂量所需的时间。目前仍需要更大规模的高质量对照试验更好地识别抗IgE单克隆抗体联合AIT的获益人群,以及治疗最佳剂量和持续时间,并评估长期效益、进行成本-效益分析。本文就抗IgE单克隆抗体在AIT中作为辅助治疗的应用进展进行综述。
Anti-IgE monoclonal antibodies have been approved for the treatment of asthma and chronic urticaria,and anti-IgE monoclonal antibodies combined with allergen immunotherapy(AIT)have attracted widespread attention as an adjunctive therapy for allergic diseases.Studies have shown that the addition of anti-IgE monoclonal antibodies during or before AIT treatment significantly reduces the frequency and severity of AIT adverse reactions,significantly improves the symptom scores,and shortens the time required to achieve maintenance doses.Larger,high-quality,placebo-controlled trials are still needed to better identify the beneficiaries of anti-IgE monoclonal antibodies in conjunction with AIT,as well as the optimal dose and duration of treatment,and to assess long-term benefits and conduct cost-benefit analysis.This article reviews the application of anti-IgE monoclonal antibodies as adjunctive therapy in AIT.
作者
李淑娴
刘金玲
何静(综述)
陈志敏(审校)
LI Shuxian;LIU Jinling;HE Jing;CHEN Zhimin(Department of Pulmonology,The Children’s Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,Hangzhou 310052,Zhejiang,China)
出处
《临床儿科杂志》
CAS
CSCD
北大核心
2024年第3期264-269,共6页
Journal of Clinical Pediatrics
基金
国家自然科学基金面上项目(No.81870023)
浙江省自然科学基金(No.LQ20H190006)
浙江省重点研发计划项目(No.2020C03062)。
